TD Cowen analyst Marc Frahm has maintained their bullish stance on SANA stock, giving a Buy rating on April 29.
Marc Frahm has given his Buy rating due to a combination of factors related to Sana Biotechnology’s recent developments and future prospects. The company reported a first-quarter loss but maintains a cash position that extends its operational runway into 2026, which provides a stable financial outlook. Additionally, Sana is making significant progress in its clinical trials, with updates expected in 2025 for its GLEAM and VIVID trials, which target various autoimmune and malignancy conditions.
Furthermore, the ongoing Phase I trial of HIP-modified human cadaver islet cells in a patient with type 1 diabetes has shown promising results, with the cells continuing to function without immune suppression at 12 weeks. This suggests long-term protection from immune recognition, which is a significant breakthrough. The stability in C-peptide production and positive mixed meal tolerance test results indicate that the islet cells are effectively producing insulin and responding to glucose spikes. These advancements, along with the anticipated filing of INDs for other promising therapies, underpin Frahm’s optimistic outlook on Sana’s stock.
According to TipRanks, Frahm is a 3-star analyst with an average return of 2.6% and a 38.68% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Janux Therapeutics Inc, and Xilio Therapeutics.
In another report released on April 29, Bank of America Securities also maintained a Buy rating on the stock with a $7.00 price target.